IDEAYA Biosciences’ (IDYA) Overweight Rating Reiterated at Stephens

Stephens reaffirmed their overweight rating on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $45.00 price target on the stock.

A number of other equities research analysts have also issued reports on the company. Citizens Jmp started coverage on IDEAYA Biosciences in a research note on Thursday, September 4th. They issued a “mkt outperform” rating and a $41.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research note on Tuesday. Barclays started coverage on IDEAYA Biosciences in a research note on Thursday, September 4th. They issued an “overweight” rating and a $40.00 target price on the stock. TD Cowen started coverage on IDEAYA Biosciences in a research note on Tuesday, July 22nd. They issued a “buy” rating on the stock. Finally, JPMorgan Chase & Co. upped their target price on IDEAYA Biosciences from $72.00 to $74.00 and gave the company an “overweight” rating in a research note on Wednesday, September 3rd. Twelve equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and an average price target of $42.75.

IDEAYA Biosciences Trading Up 0.9%

NASDAQ IDYA opened at $24.93 on Tuesday. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -6.58 and a beta of 0.12. The business’s 50 day moving average is $23.89 and its two-hundred day moving average is $20.72. IDEAYA Biosciences has a 12-month low of $13.45 and a 12-month high of $37.80.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.03). The company had revenue of $6.00 million during the quarter, compared to analyst estimates of $3.48 million. IDEAYA Biosciences’s revenue for the quarter was up NaN% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.68) EPS. Equities analysts forecast that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

Institutional Trading of IDEAYA Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in IDYA. Ameriprise Financial Inc. increased its holdings in shares of IDEAYA Biosciences by 3.6% during the 4th quarter. Ameriprise Financial Inc. now owns 288,002 shares of the company’s stock worth $7,401,000 after buying an additional 10,072 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of IDEAYA Biosciences by 37.5% during the 4th quarter. BNP Paribas Financial Markets now owns 38,692 shares of the company’s stock worth $994,000 after buying an additional 10,543 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of IDEAYA Biosciences by 5.9% during the 4th quarter. Bank of America Corp DE now owns 747,934 shares of the company’s stock worth $19,222,000 after buying an additional 41,390 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of IDEAYA Biosciences by 6.9% during the 4th quarter. Deutsche Bank AG now owns 372,979 shares of the company’s stock worth $9,586,000 after buying an additional 24,205 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of IDEAYA Biosciences by 13.5% during the 4th quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company’s stock worth $150,606,000 after buying an additional 695,263 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.